These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 26602976)

  • 1. An Indirect Comparison of Everolimus Versus Axitinib in US Patients With Advanced Renal Cell Carcinoma in Whom Prior Sunitinib Therapy Failed.
    Sherman S; Amzal B; Calvo E; Wang X; Park J; Liu Z; Lin C; Casciano R
    Clin Ther; 2015 Oct; ():. PubMed ID: 26602976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses.
    Proskorovsky I; Benedict A; Negrier S; Bargo D; Sandin R; Ramaswamy K; Desai J; Cappelleri JC; Larkin J
    BMC Cancer; 2018 Dec; 18(1):1271. PubMed ID: 30567533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
    Pal SK; Jonasch E; Signorovitch JE; Reichmann WM; Li N; Liu Z; Perez JR; Vogelzang NJ
    J Med Econ; 2016; 19(5):462-8. PubMed ID: 26652893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapy for metastatic renal cell carcinoma.
    Hofmann F; Hwang EC; Lam TB; Bex A; Yuan Y; Marconi LS; Ljungberg B
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012796. PubMed ID: 33058158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
    Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
    Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial.
    Bracarda S; Bamias A; Casper J; Negrier S; Sella A; Staehler M; Tarazi J; Felici A; Rosbrook B; Jardinaud-Lopez M; Escudier B
    Clin Genitourin Cancer; 2019 Jun; 17(3):e689-e703. PubMed ID: 31072748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4).
    Motzer RJ; Alyasova A; Ye D; Karpenko A; Li H; Alekseev B; Xie L; Kurteva G; Kowalyszyn R; Karyakin O; Neron Y; Cosgriff T; Collins L; Brechenmacher T; Lin C; Morgan L; Yang L
    Ann Oncol; 2016 Mar; 27(3):441-8. PubMed ID: 26681676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation.
    Edwards SJ; Wakefield V; Cain P; Karner C; Kew K; Bacelar M; Masento N; Salih F
    Health Technol Assess; 2018 Jan; 22(6):1-278. PubMed ID: 29393024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US.
    Perrin A; Sherman S; Pal S; Chua A; Gorritz M; Liu Z; Wang X; Culver K; Casciano R; Garrison LP
    J Med Econ; 2015 Mar; 18(3):200-9. PubMed ID: 25422989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma.
    Iacovelli R; Cossu Rocca M; Galli L; Sabbatini R; De Giorgi U; Santini D; Facchini G; Mosca A; Atzori F; Zucali P; Fornarini G; Massari F; Buti S; Ricotta R; Masini C; Toscani I; Biasco E; Guida A; Lolli C; De Lisi D; Rossetti S; Terrone C; Scartozzi M; Miggiano C; Pastorino A; Bersanelli M; Carlo-Stella G; Pinto C; Nobili E; Nolè F; Tortora G; Porta C
    Anticancer Drugs; 2018 Aug; 29(7):705-709. PubMed ID: 29846246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China.
    Shi G; Park SH; Ren H; Xue M; Lu X; Dong P; Gao X
    J Med Econ; 2018 Dec; 21(12):1150-1158. PubMed ID: 30134758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
    Vogelzang NJ; Pal SK; Signorovitch JE; Reichmann WM; Li N; Yang C; Liu Z; Perez JR; Jonasch E
    Curr Med Res Opin; 2016; 32(4):741-7. PubMed ID: 26744781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma.
    Géczi L; Bodoky G; Rokszin G; Fábián I; Torday L
    Pathol Oncol Res; 2020 Oct; 26(4):2201-2207. PubMed ID: 32291570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.
    McGregor B; Geynisman DM; Burotto M; Suárez C; Bourlon MT; Barata PC; Gulati S; Huo S; Ejzykowicz F; Blum SI; Del Tejo V; Hamilton M; May JR; Du EX; Wu A; Kral P; Ivanescu C; Chin A; Betts KA; Lee CH; Choueiri TK; Cella D; Porta C
    Eur Urol Oncol; 2023 Jun; 6(3):339-348. PubMed ID: 36842942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study).
    Grünwald V; Hilser T; Meiler J; Goebell PJ; Ivanyi P; Strauss A; Hartmann A; Bedke J; Bergmann L
    Oncol Res Treat; 2022; 45(5):272-280. PubMed ID: 35045416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
    Motzer R; Porta C; Alekseev B; Rha SY; Choueiri TK; Mendez-Vidal MJ; Hong SH; Kapoor A; Goh JC; Eto M; Bennett L; Wang J; Pan JJ; Saretsky TL; Perini RF; He CS; Mody K; Cella D
    Lancet Oncol; 2022 Jun; 23(6):768-780. PubMed ID: 35489363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.
    Escudier B; Michaelson MD; Motzer RJ; Hutson TE; Clark JI; Lim HY; Porfiri E; Zalewski P; Kannourakis G; Staehler M; Tarazi J; Rosbrook B; Cisar L; Hariharan S; Kim S; Rini BI
    Br J Cancer; 2014 Jun; 110(12):2821-8. PubMed ID: 24823696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line treatment after sunitinib therapy in patients with renal cell carcinoma: a comparison of axitinib and mammalian target of rapamycin inhibitors.
    Tamada S; Iguchi T; Kato M; Yasuda S; Yamasaki T; Nakatani T
    Oncotarget; 2018 Dec; 9(97):37017-37025. PubMed ID: 30651932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101.
    Tomita Y; Motzer RJ; Choueiri TK; Rini BI; Miyake H; Oya M; Albiges L; Aizawa M; Umeyama Y; Wang J; di Pietro A; Schmidinger M
    ESMO Open; 2023 Dec; 8(6):102034. PubMed ID: 37866029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.